Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | EVP & Chief Technology Officer | May 07, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,256 |
Reported balance
After 2026-05-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-07 · Tax withholding · Disposed 556 · Balance 42,256 F1: These shares include 350 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include 350 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2021 Filed Mar 22, 2021 22:34 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,401 | $244.42 | $342,432.42 |
DisclosureSEC source: 0001127602-21-011715 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,494 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,673 RSUs which vest on 5/1/2021; 335 RSUs which vest on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 8,597 RSUs which vest in installments of 4,234 on 11/2/2021 and 4,363 on 11/2/2022; 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,310 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 02, 2021 Filed Mar 5, 2021 01:35 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 2,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-009483 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,715 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,673 RSUs which vest on 5/1/2021; 335 RSUs which vest on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 8,597 RSUs which vest in installments of 4,234 on 11/2/2021 and 4,363 on 11/2/2022; 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,152 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 01:59 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 2,300 | $0.00 Strike: $54.69 | $0.00 |
DisclosureSEC source: 0001127602-21-006060 · form4.xml · derivative · entry 3 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires 2021-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 01:59 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,147 | $237.21 | $272,079.87 |
DisclosureSEC source: 0001127602-21-006060 · form4.xml · nonDerivative · entry 2 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,912 F1 · balance_after: Non-market exercise of 2,300 stock options expiring April 25, 2021 wherein 1,147 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,673 RSUs which vest on 5/1/2021; 335 RSUs which vest on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 8,597 RSUs which vest in installments of 4,234 on 11/2/2021 and 4,363 on 11/2/2022; 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 1,152 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 01:59 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 2,300 | $54.69 | $125,787.00 |
DisclosureSEC source: 0001127602-21-006060 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 00:06 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,125 | $216.94 | $460,997.50 |
DisclosureSEC source: 0001127602-20-028206 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,619 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,673 RSUs which vest on 5/1/2021; 335 RSUs which vest on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 8,597 RSUs which vest in installments of 4,234 on 11/2/2021 and 4,363 on 11/2/2022; 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,012 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 05, 2020 Filed May 8, 2020 01:04 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 29,050 | $0.00 Strike: $236.36 | $0.00 |
DisclosureSEC source: 0001127602-20-015865 · form4.xml · derivative · entry 2 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,050 Underlying: Common Stock · 29,050 shares Expires 2030-05-05 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively. Read SEC document |
| May 05, 2020 Filed May 8, 2020 01:04 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-015865 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,408 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,673 RSUs which vest on 5/1/2021; 335 RSUs which vest on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022; 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 926 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2020 Filed May 5, 2020 23:57 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 185 | $230.98 | $42,731.30 |
DisclosureSEC source: 0001127602-20-015556 · form4.xml · nonDerivative · entry 2 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,939 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,673 RSUs which vest on 5/1/2021; 335 RSUs which vest on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022; and 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 926 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 01, 2020 Filed May 5, 2020 23:57 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,046 | $239.22 | $250,224.12 |
DisclosureSEC source: 0001127602-20-015556 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,124 Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:04 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 168 | $236.28 | $39,695.04 |
DisclosureSEC source: 0001127602-20-014704 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,170 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 3,297 RSUs which vest in installments of 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022; and 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,138 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 22:09 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,855 | $198.76 | $368,699.80 |
DisclosureSEC source: 0001127602-20-011873 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,338 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 3,297 RSUs which vest in installments of 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 1,014 RSUs which vest in installments of 334 on 4/27/2020, 335 on 4/27/2021 and 345 on 4/27/2022; 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022; and 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,157 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 01:12 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 1,480 | $0.00 Strike: $58.43 | $0.00 |
DisclosureSEC source: 0001127602-20-010170 · form4.xml · derivative · entry 3 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,480 shares Expires 2020-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 01:12 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 780 | $210.65 | $164,307.00 |
DisclosureSEC source: 0001127602-20-010170 · form4.xml · nonDerivative · entry 2 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,985 F1 · balance_after: Non-market exercise of 1,480 stock options expiring April 26, 2020 wherein 780 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 3,297 RSUs which vest in installments of 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 1,014 RSUs which vest in installments of 334 on 4/27/2020, 335 on 4/27/2021 and 345 on 4/27/2022; 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022; and 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 978 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 01:12 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 1,480 | $58.43 | $86,476.40 |
DisclosureSEC source: 0001127602-20-010170 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 00:58 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-009712 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,285 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 3,297 RSUs which vest in installments of 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 1,014 RSUs which vest in installments of 334 on 4/27/2020, 335 on 4/27/2021 and 345 on 4/27/2022; 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022; and 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 978 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:06 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 39,382 | $0.00 Strike: $177.31 | $0.00 |
DisclosureSEC source: 0001127602-19-017653 · form4.xml · derivative · entry 3 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,382 Underlying: Common Stock · 39,382 shares Expires 2029-05-03 F4 · derivative.exercise_date: These stock options are exercisable in three annual installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:06 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 4,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-017653 · form4.xml · nonDerivative · entry 2 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,075 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 3,297 RSUs which vest in installments of 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 1,014 RSUs which vest in installments of 334 on 4/27/2020, 335 on 4/27/2021 and 345 on 4/27/2022; 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022; and 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 479 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:06 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 174 | $176.50 | $30,711.00 |
DisclosureSEC source: 0001127602-19-017653 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,564 Read SEC document |
| May 01, 2019 Filed May 3, 2019 21:54 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 851 | $179.32 | $152,604.04 |
DisclosureSEC source: 0001127602-19-017349 · form4.xml · nonDerivative · entry 2 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,738 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in installments of 338 on 5/3/2019 and 348 on 5/3/2020; 3,297 RSUs which vest in installments of 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 1,014 RSUs which vest in installments of 334 on 4/27/2020, 335 on 4/27/2021 and 345 on 4/27/2022; and 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 507 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 01, 2019 Filed May 3, 2019 21:54 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 163 | $179.32 | $29,229.68 |
DisclosureSEC source: 0001127602-19-017349 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,859 Read SEC document |
| March 22, 2019 Filed Mar 25, 2019 23:41 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,769 | $191.89 | $339,453.41 |
DisclosureSEC source: 0001127602-19-013166 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,752 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in installments of 338 on 5/3/2019 and 348 on 5/3/2020; 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; 1,014 RSUs which vest in installments of 334 on 4/27/2020, 335 on 4/27/2021 and 345 on 4/27/2022; and 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 617 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 06, 2019 Filed Mar 9, 2019 00:44 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-010659 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,324 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 686 RSUs which vest in installments of 338 on 5/3/2019 and 348 on 5/3/2020; 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; 1,014 RSUs which vest in installments of 334 on 4/27/2020, 335 on 4/27/2021 and 345 on 4/27/2022; and 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 450 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 23:25 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 115 | $192.11 | $22,092.65 |
DisclosureSEC source: 0001127602-19-003515 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,648 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 686 RSUs which vest in installments of 338 on 5/3/2019 and 348 on 5/3/2020; 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; 1,014 RSUs which vest in installments of 334 on 4/27/2020, 335 on 4/27/2021 and 345 on 4/27/2022; and 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 450 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 23:20 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 12,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-032310 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,618 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 11/2/2020, 11/2/2021 and 11/2/2022, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 313 RSUs which vest fully in one installment on 1/30/2019; 686 RSUs which vest in installments of 338 and 348 on 5/3/2019 and 5/3/2020, respectively; 4,920 RSUs which vest in installments of 1,623, 1,624 and 1,673 on 5/1/2019, 5/1/2020 and 5/1/2021, respectively; 984 RSUs which vest in installments of 324, 325 and 335 on 5/1/2019, 5/1/2020 and 5/1/2021, respectively; 1,014 RSUs which vest in installments of 334, 335 and 345 on 4/27/2020, 4/27/2021 and 4/27/2022, respectively. F3 · balance_after: These shares include 338 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.